Gabapentin HClGABA analog CAS# 60142-95-2 |
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 60142-95-2 | SDF | Download SDF |
| PubChem ID | 6453919 | Appearance | Powder |
| Formula | C9H18ClNO2 | M.Wt | 207.7 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 50 mg/mL (240.73 mM; Need ultrasonic) | ||
| Chemical Name | 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydrochloride | ||
| SMILES | [H+].[Cl-].NCC1(CCCCC1)CC(O)=O | ||
| Standard InChIKey | XBUDZAQEMFGLEU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C9H17NO2.ClH/c10-7-9(6-8(11)12)4-2-1-3-5-9;/h1-7,10H2,(H,11,12);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Gabapentin HCl Dilution Calculator
Gabapentin HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.8146 mL | 24.0732 mL | 48.1464 mL | 96.2927 mL | 120.3659 mL |
| 5 mM | 0.9629 mL | 4.8146 mL | 9.6293 mL | 19.2585 mL | 24.0732 mL |
| 10 mM | 0.4815 mL | 2.4073 mL | 4.8146 mL | 9.6293 mL | 12.0366 mL |
| 50 mM | 0.0963 mL | 0.4815 mL | 0.9629 mL | 1.9259 mL | 2.4073 mL |
| 100 mM | 0.0481 mL | 0.2407 mL | 0.4815 mL | 0.9629 mL | 1.2037 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treatepilepsy, and currently is also used to relieve neuropathic pain.
- Cephaelin dihydrobromide
Catalog No.:BCC8142
CAS No.:6014-81-9
- Coulteropine
Catalog No.:BCN7420
CAS No.:6014-62-6
- Cucurbitacin S
Catalog No.:BCN2676
CAS No.:60137-06-6
- Ercalcitriol
Catalog No.:BCC1556
CAS No.:60133-18-8
- Pterodondiol
Catalog No.:BCN4110
CAS No.:60132-35-6
- Paniculoside III
Catalog No.:BCN7503
CAS No.:60129-65-9
- Paniculoside II
Catalog No.:BCN4109
CAS No.:60129-64-8
- Paniculoside I
Catalog No.:BCN4108
CAS No.:60129-63-7
- 3-(2-Hydroxyphenyl)-2-propenal
Catalog No.:BCN4107
CAS No.:60125-23-7
- Baimantuoluoside C
Catalog No.:BCN8009
CAS No.:60124-17-6
- Petasitenine
Catalog No.:BCN2113
CAS No.:60102-37-6
- Isosativan
Catalog No.:BCN4106
CAS No.:60102-29-6
- Gabapentin
Catalog No.:BCC3783
CAS No.:60142-96-3
- 11,12-Dihydro-7-hydroxyhedychenone
Catalog No.:BCN7382
CAS No.:60149-07-7
- TWS119
Catalog No.:BCC4512
CAS No.:601514-19-6
- Sodium 4-Aminosalicylate
Catalog No.:BCC4609
CAS No.:6018-19-5
- Arecaidine hydrochloride
Catalog No.:BCN8530
CAS No.:6018-28-6
- Corypalmine
Catalog No.:BCN4111
CAS No.:6018-40-2
- Methyl 15-hydroxy-7-oxodehydroabietate
Catalog No.:BCN7674
CAS No.:60188-95-6
- Licoflavonol
Catalog No.:BCN6828
CAS No.:60197-60-6
- Taspine
Catalog No.:BCN6956
CAS No.:602-07-3
- Thiocolchicoside
Catalog No.:BCN8442
CAS No.:602-41-5
- 1,2-dihydroxy-3-methyl-anthracene-9,10-dione
Catalog No.:BCN1404
CAS No.:602-63-1
- Coptisine chloride
Catalog No.:BCN6321
CAS No.:6020-18-4
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.[Pubmed:26352507]
Pain Med. 2016 Feb;17(2):230-8.
OBJECTIVE: This study evaluates the ability of four commonly used analgesics (ketamine HCl, gabapentin, clonidine HCl, and baclofen), when incorporated into two transdermal compounding bases, Lipoderm and Lipoderm ActiveMax, to penetrate human cadaver trunk skin in vitro, using the Franz finite dose model. DESIGN: In vitro experimental study. Methods. Ketamine HCl 5% w/w, gabapentin 10% w/w, clonidine HCl 0.2% w/w, and baclofen 2% w/w were compounded into two transdermal bases, Lipoderm and Lipoderm ActiveMax. Each compounded drug formulation was tested on skin from three different donors and three replicate skin sections per donor. The Franz finite dose model was used in this study to evaluate the percutaneous absorption and distribution of drugs within each formulation. RESULTS: Rapid penetration to peak flux was detected for gabapentin and baclofen at approximately 1 hour after application. Clonidine HCl also had a rapid penetration to peak flux occurring approximately 1 hour after application and had a secondary peak at approximately 40 hours. Ketamine HCl exhibited higher overall absorption rates than the other drugs, and peaked at 6-10 hours. Similar patterns of drug distribution within the skin were also observed using both transdermal bases. CONCLUSIONS: This study suggests that the combination of these 4 analgesic drugs can be successfully delivered transdermally, using either Lipoderm or Lipoderm ActiveMax. Compounded transdermal drug preparations may then provide physicians with an alternative to traditional oral pain management regimens that can be personalized to the specific patient with the potential for enhanced pain control.
